(4S)-3-[2-[1-(6-piperazin-1-yloxy-3-pyridinyl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one
C21H29N7O3 — CID 153328252
Data last refreshed: (MolForge compound catalog, from PubChem)
About (4S)-3-[2-[1-(6-piperazin-1-yloxy-3-pyridinyl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one
(4S)-3-[2-[1-(6-piperazin-1-yloxy-3-pyridinyl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one (PubChem CID 153328252) has the molecular formula C21H29N7O3 and a molecular weight of 427.51 g/mol. Its IUPAC name is (4S)-3-[2-[1-(6-piperazin-1-yloxy-3-pyridinyl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one.
Molecular Properties
| Compound Name | (4S)-3-[2-[1-(6-piperazin-1-yloxy-3-pyridinyl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one |
|---|---|
| PubChem CID | 153328252 |
| Molecular Formula | C21H29N7O3 |
| Molecular Weight | 427.51 g/mol |
| Exact Mass | 427.23 |
| IUPAC Name | (4S)-3-[2-[1-(6-piperazin-1-yloxy-3-pyridinyl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one |
| SMILES | CC(Nc1nccc(N2C(=O)OC[C@@H]2C(C)C)n1)c1ccc(ON2CCNCC2)nc1 |
| InChI | InChI=1S/C21H29N7O3/c1-14(2)17-13-30-21(29)28(17)18-6-7-23-20(26-18)25-15(3)16-4-5-19(24-12-16)31-27-10-8-22-9-11-27/h4-7,12,14-15,17,22H,8-11,13H2,1-3H3,(H,23,25,26)/t15?,17-/m1/s1 |
| InChIKey | PWTVBKNLENHTPJ-OMOCHNIRSA-N |
| XLogP | 2.22 |
| TPSA | 104.74 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 427.51 |
| LogP ≤ 5 | 2.22 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 153328252 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.